Acelyrin (SLRN) News Today $2.43 -0.15 (-5.81%) Closing price 04:00 PM EasternExtended Trading$2.52 +0.09 (+3.70%) As of 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating The Merger - SLRN, TURN, BHLB, MHLDMarch 30, 2025 | morningstar.comInsider Selling: Acelyrin, Inc. (NASDAQ:SLRN) Insider Sells 3,913 Shares of StockAcelyrin, Inc. (NASDAQ:SLRN - Get Free Report) insider Amar Murugan sold 3,913 shares of the business's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $2.74, for a total transaction of $10,721.62. Following the transaction, the insider now directly owns 121,587 shares in the company, valued at approximately $333,148.38. The trade was a 3.12 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.March 20, 2025 | marketbeat.comInsider Selling: Acelyrin, Inc. (NASDAQ:SLRN) CEO Sells 17,986 Shares of StockAcelyrin, Inc. (NASDAQ:SLRN - Get Free Report) CEO Mina Kim sold 17,986 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $2.74, for a total transaction of $49,281.64. Following the completion of the transaction, the chief executive officer now directly owns 671,753 shares in the company, valued at $1,840,603.22. This represents a 2.61 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.March 20, 2025 | marketbeat.comAcelyrin (NASDAQ:SLRN) Releases Quarterly Earnings Results, Beats Expectations By $0.07 EPSAcelyrin (NASDAQ:SLRN - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.79) earnings per share for the quarter, beating analysts' consensus estimates of ($0.86) by $0.07.March 20, 2025 | marketbeat.comInsider Selling: Acelyrin, Inc. (NASDAQ:SLRN) Insider Sells 3,913 Shares of StockMarch 20, 2025 | insidertrades.comAcelyrin (SLRN) Projected to Post Quarterly Earnings on ThursdayAcelyrin (NASDAQ:SLRN) will be releasing earnings before the market opens on Thursday, March 27, Financial Modeling Prep reports.March 20, 2025 | marketbeat.comAcelyrin, Inc. (SLRN): One of the Best Short-Term Stocks to Buy Right NowMarch 18, 2025 | msn.comACELYRIN Adopts Limited-Duration Stockholder Rights PlanMarch 13, 2025 | globenewswire.comAcelyrin: Potential Buyout Led By Concentra BiosciencesMarch 12, 2025 | seekingalpha.comAcelyrin, Inc. (NASDAQ:SLRN) Holdings Decreased by General Atlantic L.P.General Atlantic L.P. trimmed its position in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 6.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,695,327 shares of the company's stock after selling 194,341 shares during theMarch 11, 2025 | marketbeat.comIs Acelyrin, Inc. (SLRN) the Best Micro Cap Stock to Buy Now?March 7, 2025 | insidermonkey.comACELYRIN, INC.: ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed MergerMarch 4, 2025 | finanznachrichten.deAcelyrin says Concentra indication not expected to result in superior proposalMarch 4, 2025 | markets.businessinsider.comAcelyrin falls as Acelyrin reaffirms deal commitmentMarch 4, 2025 | msn.comAcelyrin, Alumis reaffirm strategic, financial rationale of proposed mergerMarch 4, 2025 | markets.businessinsider.comACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed MergerMarch 4, 2025 | globenewswire.comACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis MergerMarch 4, 2025 | globenewswire.comAcelyrin, Inc. (NASDAQ:SLRN) Sees Large Decrease in Short InterestAcelyrin, Inc. (NASDAQ:SLRN - Get Free Report) saw a significant decrease in short interest in the month of February. As of February 15th, there was short interest totalling 4,720,000 shares, a decrease of 19.6% from the January 31st total of 5,870,000 shares. Currently, 6.5% of the shares of the company are short sold. Based on an average trading volume of 1,930,000 shares, the days-to-cover ratio is currently 2.4 days.March 4, 2025 | marketbeat.comAcelyrin (NASDAQ:SLRN) Stock Price Up 1.2% - Should You Buy?Acelyrin (NASDAQ:SLRN) Shares Up 1.2% - Still a Buy?February 27, 2025 | marketbeat.comAcelyrin Stock Jumps on Concentra Acquisition InterestFebruary 21, 2025 | marketwatch.comAcelyrin Stock Jumps on Concentra Acquisition InterestFebruary 21, 2025 | marketwatch.comAcelyrin confirms unsolicited indication of interest from Concentra BiosciencesFebruary 21, 2025 | markets.businessinsider.comAcelyrin jumps 11% on acquisition offer from Concentra BiosciencesFebruary 21, 2025 | msn.comACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra BiosciencesFebruary 20, 2025 | globenewswire.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Acelyrin, Inc. BuyoutFebruary 12, 2025 | markets.businessinsider.comSLRN stock touches 52-week low at $1.85 amid market challengesFebruary 11, 2025 | msn.comAlumis price target lowered to $26 from $32 at OppenheimerFebruary 10, 2025 | markets.businessinsider.comPiper Sandler Sticks to Their Buy Rating for ACELYRIN, INC. (SLRN)February 8, 2025 | markets.businessinsider.comACELYRIN, INC. (SLRN) Receives a Buy from Wells FargoFebruary 8, 2025 | markets.businessinsider.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.February 7, 2025 | prnewswire.comAcelyrin Inc trading halted, news pendingFebruary 7, 2025 | markets.businessinsider.comSLRN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ACELYRIN, Inc. Is Fair to ShareholdersFebruary 6, 2025 | businesswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Acelyrin, Inc. - SLRNFebruary 6, 2025 | prnewswire.comAlumis and ACELYRIN Agree to Merge in All-Stock DealFebruary 6, 2025 | marketwatch.comAlumis and ACELYRIN announce merger in all-stock dealFebruary 6, 2025 | msn.comAlumis, Acelyrin to merge in all-stock transactionFebruary 6, 2025 | markets.businessinsider.comShareholder Alert: Ademi & Fruchter LLP investigates whether ACELYRIN, INC. is obtaining a Fair Price for its Public ShareholdersFebruary 6, 2025 | businesswire.comAlumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated DiseasesFebruary 6, 2025 | globenewswire.comSLRN stock touches 52-week low at $1.9 amid market challengesJanuary 28, 2025 | msn.comJPMorgan Chase & Co. Cuts Stake in Acelyrin, Inc. (NASDAQ:SLRN)JPMorgan Chase & Co. lowered its stake in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 67.3% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 850,661 shares of the company's stock after selling 1,747,642 shares during the quarter. JPJanuary 18, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for Acelyrin Q1 Earnings?Acelyrin, Inc. (NASDAQ:SLRN - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Acelyrin in a research note issued on Tuesday, January 7th. HC Wainwright analyst E. Bodnar anticipates that the company will earn ($0.44) per sJanuary 9, 2025 | marketbeat.comCautious Hold Rating for ACELYRIN, INC. Amid Uncertainties in Lonigutamab’s Efficacy and DosingJanuary 8, 2025 | markets.businessinsider.comACELYRIN, INC. (SLRN) Receives a Buy from TD CowenJanuary 7, 2025 | markets.businessinsider.comAcelyrin price target lowered to $3 from $6 at CitiJanuary 7, 2025 | markets.businessinsider.comCitigroup Has Lowered Expectations for Acelyrin (NASDAQ:SLRN) Stock PriceCitigroup cut their price target on shares of Acelyrin from $6.00 to $3.00 and set a "neutral" rating on the stock in a research note on Tuesday.January 7, 2025 | marketbeat.comAcelyrin falls after updating mid-stage trial data for eye disease drugJanuary 7, 2025 | msn.comAcelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionJanuary 7, 2025 | benzinga.comAcelyrin (NASDAQ:SLRN) Price Target Cut to $6.00 by Analysts at HC WainwrightHC Wainwright reduced their price target on shares of Acelyrin from $8.00 to $6.00 and set a "neutral" rating on the stock in a research report on Tuesday.January 7, 2025 | marketbeat.comAcelyrin announces additional lonigutamab data, design for LONGITUDE programJanuary 7, 2025 | markets.businessinsider.comACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye DiseaseJanuary 6, 2025 | globenewswire.com Remove Ads Get Acelyrin News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRN and its competitors with MarketBeat's FREE daily newsletter. Email Address SLRN Media Mentions By Week SLRN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLRN News Sentiment▼0.890.61▲Average Medical News Sentiment SLRN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLRN Articles This Week▼12▲SLRN Articles Average Week Remove Ads Get Acelyrin News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GPCR News SYRE News ELVN News COLL News NRIX News VIR News PAHC News XERS News OCS News ZYME News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLRN) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredWall St. Icon: Looming Financial Tsunami Could Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event could hit the America...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acelyrin, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acelyrin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SLRN Stock Free SLRN Stock Alerts